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A large body of experimental and clinical evidence has strongly suggested that
monoamines play an important role in regulating epileptogenesis, seizure susceptibility,
convulsions, and comorbid psychiatric disorders commonly seen in people with epilepsy
(PWE). However, neither the relative significance of individual monoamines nor their
interaction has yet been fully clarified due to the complexity of these neurotransmitter
systems. In addition, epilepsy is diverse, with many different seizure types and epilepsy
syndromes, and the role played by monoamines may vary from one condition to another.
In this review, we will focus on the role of serotonin, dopamine, noradrenaline, histamine,
and melatonin in epilepsy. Recent experimental, clinical, and genetic evidence will be
reviewed in consideration of the mutual relationship of monoamines with the other
putative neurotransmitters. The complexity of epileptic pathogenesis may explain why the
currently available drugs, developed according to the classic drug discovery paradigm of
“one-molecule-one-target,” have turned out to be effective only in a percentage of PWE.
Although, no antiepileptic drugs currently target specifically monoaminergic systems,
multi-target directed ligands acting on different monoaminergic proteins, present on both
neurons and glia cells, may represent a new approach in the management of seizures,
and their generation as well as comorbid neuropsychiatric disorders.
Keywords: monoamine receptors, multi-target direct ligands, epilepsy, epileptogenesis, antiepileptic drugs,
quad-partite synapse, astrocytes, microglia
INTRODUCTION
Epilepsy is a complex chronic group of neurological disorders that affects ∼60 million people
worldwide, with 6 million in Europe alone (Baulac et al., 2015).
Epilepsy is characterized by spontaneous and recurrent unprovoked seizures (bursts of neuronal
hyperactivity) arising in the brain that can be “focal” or “partial” if they remain confined to their
area of origin, or “generalized” if they spread to the entire cerebral hemispheres. Recently, seizures
have been classified in focal and generalized convulsive and non-convulsive epilepsies according to
their different electrophysiological and clinical characteristics (Berg et al., 2010). Epilepsy can be
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symptomatic, for example, due to stroke, infections, brain
tumors, prolonged febrile seizures, and other occurrences of
status epilepticus (SE). Additionally, about 40% of all epilepsies,
especially during childhood, and adolescence (Guerrini, 2006),
are idiopathic epilepsies. Several defects in ion channel or
neurotransmitter genes or proteins that control brain excitability
have been recently identified in some idiopathic epilepsies
(Scharfman, 2007). In addition, various epidemiological and
family studies have suggested a genetic basis of epilepsy (Myers
and Mefford, 2015). A number of genes have been associated
with epilepsy disorders in a Mendelian manner (Harden,
2002). However, it has been suggested that most epilepsies
have a polygenic basis, with multiple genetic susceptibility
factors which have only partial effects, but act in concert,
and interact with various environmental factors (Ferraro and
Buono, 2006; Tan and Berkovic, 2010). The genes associated with
epilepsy are involved in different molecular pathways, including
the regulation of development and function of the nervous
system (Holmes and Noebels, 2016). Although, the majority
of genes associated with epilepsies are coding for different
voltage and ligand-gated ion channels or regulating the action
of excitatory or inhibitory neurotransmission (i.e., CHRNA4,
CHRNA2, CHRNB2, GABRG2, GABRA1, KCNQ2, KCNQ3,
SCN1B, SCN1A, SCN2A), the potential role of several other
genes (i.e., ARX, CDKL5, LGI1, PCDH19, SLC2A1, SPTAN1,
STXBP1) in the epilepsy has also been also suggested (Rees, 2010;
Hildebrand et al., 2013).
Genetics therefore plays a role, although a complex one, in
almost all acquired epilepsies.
The lifetime prevalence of epilepsy is 1–2%, and it affects
individuals of all ages regardless of gender or socio-economic
status. Epilepsy is a significant health concern for the human
population and people with epilepsy (PWE) carry a risk of
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premature mortality, with a life expectancy 10 years less than the
general population (Gaitatzis et al., 2004).
There is currently no cure or prevention for epilepsy. Most,
if not all of the approved antiepileptic drugs (AEDs) are not
truly “antiepileptic” but merely “anti-seizures” (Van Liefferinge
et al., 2013). Indeed, the AEDs do not stop epileptogenesis, the
process of converting a normal brain to a brain with epilepsy, but
at the most they reach complete seizure control. Unfortunately,
not all PWE respond to the therapies, with 30–40% of them
possessing pharmacoresistant epilepsy (Kobau et al., 2008).
Although, the efforts in antiepileptic drug development have
not solved the issue, they have encouraged experimental and
clinical research to focus on different mechanisms involved in
the neurological disorder. Indeed, many candidate processes
and molecular targets are currently under intense scrutiny
and hopefully will improve treatment and quality of life
of PWE.
Monoamines are major neuromodulator systems in the
central nervous system (CNS) and compelling evidence
accumulated in the last 30 years has also established their pivotal
role in epilepsy (Kobayashi and Mori, 1977; Kurian et al., 2011).
Serotonin (5-HT; Bagdy et al., 2007; Guiard and Di Giovanni,
2015), dopamine (DA; Bozzi and Borrelli, 2013), noradrenaline
(NA; Giorgi et al., 2004), histamine (Bhowmik et al., 2012), and
melatonin (MT; Tchekalarova et al., 2015b; Brigo and Igwe,
2016) are all known to halt seizure activity.
Further proof of monoaminergic involvement in the
pathogenesis of epilepsy is the evidence that depression, bipolar
disorders, and other neuropsychiatric disorders classically
related to monoamine dysfunctions, may augment the risk
of seizures and/or vice versa. As matter of fact, PWE with
longer duration of active epilepsy show higher comorbidity of
depressive disorders, bipolar disorder and anxiety (Rocha et al.,
2014), and in depressed patients there is a higher rate of epilepsy
compared to general population (Garcia, 2012). It has been
suggested that epilepsy and mood disorders may be different
manifestations of the same disturbances in transmission and/or
signal transduction mediated by monoamines, hyperactivity of
the hypothalamic-pituitary-adrenal axis, and CNS inflammation
(Rocha et al., 2014). As both epilepsy and monoamine-based
neuropsychiatric disorders are complex diseases that imply
changes in multiple neurotransmitters and both neuronal
and glial cells activity, a comprehensive understanding of the
underlying mechanisms is still in its infancy. Nevertheless, this
evidence of dual link between these two disorders suggest that
drugs targeting monoamines may be useful for both epilepsy and
its neuropsychiatric comorbidities (Guiard and Di Giovanni,
2015; Venzi et al., 2016).
Although, the role of monoamines in epilepsy was reviewed
for the first time by Kobayashi and Mori (1977), followed
by intensive exploration in pre-clinical and clinical research
over the last 40 years, this has not led to new treatments.
Indeed, the questions asked by Kobayashi and Mori (1977) “Is
there an abnormal metabolism of monoamines in the brain of
epileptic patients? If so, how is it related to the elaboration or
maintenance of epileptic seizures?” do not yet have definitive
answers.
Frontiers in Neuroscience | www.frontiersin.org 2 November 2016 | Volume 10 | Article 492
Svob Strac et al. Monoamines in Epilepsy
Compelling evidence shows that monoaminergic systems
appear dysregulated in animal (Szabo et al., 2015) and human
epileptic brain and increased monoamines and metabolite levels
in the cerebrospinal fluid (CSF) of PWE have been consistently
observed (Pintor et al., 1990; Naffah-Mazzacoratti et al., 1996).
Nevertheless, the elevated levels of 5-HT and DA metabolites
during epilepsy may represent an epiphenomenon, rather than
a concerted strategy of local or distal neurons to contain
an epileptogenic focus (Lowy and Meltzer, 1988). Indeed, the
rate of monoaminergic metabolism (i.e., synthesis, uptake, and
clearance) does not significantly correlate with the epileptic
condition in baboon (Szabo et al., 2015). Moreover, it has recently
been shown that receptor antagonism completely prevented
all kainic acid-induced increases in extracellular hippocampal
5-HT levels in rats without affecting seizure development
per se. This result suggested a lack of a direct relationship
between seizure susceptibility and alterations in hippocampal
5-HT levels, at least in this rat model (Tchekalarova et al.,
2015b).
These findings, however, do not necessarily exclude the
monoaminergic system as a potential source of pathogenesis
in epilepsy and sudden unexpected death in epilepsy (SUDEP;
Richerson and Buchanan, 2011).
As a further complication, monoamines seem to have a
dual effect being proconvulsant when in high concentration
in the epileptic foci. Indeed, within a certain concentration
range, intrahippocampally applied 5-HT contributed to the
prevention of hippocampally evoked limbic seizures. On the
other hand, excessive 5-HT increases worsened seizure outcome
(Clinckers et al., 2004) and elevated, endogenous noradrenergic
transmission is for example an etiological factor in some cases of
epilepsy (Fitzgerald, 2010).
In the following sections of this review, we will focus on
the role of different monoamines in seizure onset and spread,
discussing anatomical, pharmacological, and genetic evidence
obtained in animal and human studies. We will provide the
rationale for the use of drugs targeting monoamines or their
related molecules in epilepsy, some already representing good
examples of multi-target directed drugs. We finish by exploring
the interesting possibility that the monoaminergic treatment may
cure the dysfunction of the quad-partite synapse acting at the
level of their different components, i.e., (pre- and postsynaptic)
neurons, astrocytes, and microglia cells.
MONOAMINES IN EPILEPSY:
PRECLINICAL AND CLINICAL EVIDENCE
Serotonergic System in Epilepsy
It goes without saying that 5-HT is involved in epilepsy
mechanisms. According to a variety of recent findings,
neurodevelopmental alterations of serotonergic circuits in
mice are crucial in controlling seizure susceptibility to the
well-established chemoconvulsant kainic acid (KA; i.e., a
glutamatergic kainate receptor agonist) in later life (Tripathi and
Bozzi, 2015). Clinical presentations of human epilepsy have often
been attributed to deficiencies of cerebral monoamines, including
5-HT (Kurian et al., 2011). Serotonin (but also DA) enhancement
may even be involved to a certain extent in the mechanisms of
action of several clinically used antiepileptic drugs (Yan et al.,
1992; Ahmad et al., 2005; Biton, 2007).
Nevertheless, the picture is not always that clear-cut. The
classical view is that the monoamine enhancing antidepressant
drugs are contraindicated in PWE, or should at least be used
with caution. Against this assumption, more and more reports
provided evidence that several 5-HT enhancing antidepressants
were not proconvulsant but rather displayed anticonvulsant
properties (Hamid and Kanner, 2013). Dailey and Naritoku
(1996) deducted that non-monoaminergic off-target effects of
antidepressants are most likely responsible for the increased risk
of seizures.
The most straightforward answer to the question—why 5-HT
seems to exert such a complex role in themodulation of enhanced
brain excitability and epilepsy phenomena—is of course the fact
that 5-HT interacts with a variety of different receptor subtypes
linked to divergent signal transduction cascades, thereby often
exerting opposing control on cell membrane potentials (De
Deurwaerdere and Di Giovanni, 2016). Moreover, these 5-HTR
subtypes are differently distributed in distinct brain areas and
diverse brain circuitries involved in various types of epilepsy.
Moreover, as will be illustrated in following sections, the same
holds true for the other monoamines described within this
review.
For the remainder of this 5-HT section, we will focus merely
on 5-HTR subtype-specific seizure-modulating actions. Most
evidence can be found on the roles of 5-HT1R and 5-HT2R
subtypes and the 5-HT3R, while—to the best of our knowledge—
less literature is available with regard to the possible involvement
of 5-HT4 and 5-HT6Rs in epilepsymechanisms. No data has been
published on 5-HT5Rs in epilepsy. Finally, the involvement of the
5-HT7R in mechanisms of epilepsy is still ambiguous (Ciranna
and Catania, 2014; Nikiforuk, 2015).
Within the scope of the current manuscript, it will be
impossible to review all the available data to date, but we will
focus on the most prominent and/or recent findings. We also
refer to the review paper by Panczyk et al. (2015) who listed the
evidence for the involvement of 5-HT1A, 5-HT2C, 5-HT3, 5-HT4,
and 5-HT7Rs as well as the 5-HT transporter (SERT) in epilepsy
(Panczyk et al., 2015).
With regard to the 5-HT2AR and its seizure modulating
effects, literature is abundant but also very complex. For a
complete and recent overview on the role of the 5-HT2AR in
rodent epilepsy models, we refer to the detailed review by Guiard
and Di Giovanni (2015). They summarized the evidence for
5-HT2AR modulation in both generalized and focal epilepsies,
and concluded that both proconvulsant and anticonvulsant roles
have been established for this 5-HT2AR subtype, depending on
the dose of the ligands used, the experimental rodent model
investigated and the different populations of the receptors. At
high doses of the 5-HT2AR ligands, proconvulsant effects were
often noted which may be attributed—at least partly—to other
non-selective off-target effects (Guiard and Di Giovanni, 2015).
Because of this complexity, we refer the readers to this in deep
review.
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Focal Seizures
Human data
In PWE suffering from TLE, hippocampal 5-HT depletion (da
Fonseca et al., 2015) and reduced 5-HT1AR availability have been
observed. The latter somatodendritic 5-HT1A autoreceptor is
one of the best characterized subtypes of the 14 known 5-HTRs
and is clearly implicated in seizure modulation. A large body of
evidence on this receptor subtype in epilepsy has arisen from
many positron emission tomography (PET) studies in PWE,
and reduced 5-HT1AR binding in the epileptic focus has been
repeatedly and consistently found in these temporal lobe epilepsy
(TLE) patients (Hasler et al., 2007; Lothe et al., 2008; Giovacchini
et al., 2009; Assem-Hilger et al., 2010). All of these studies point
to the fact that diminished 5-HT1AR expression and subsequent
less activation by endogenous 5-HT may lead to the epileptic
phenotype. PET imaging of brain 5-HT1ARs has also helped in
the correct identification of the epileptogenic zone during the
preoperative evaluation of temporal lobe of PWE subjected to
epilepsy surgery (Didelot et al., 2008; Theodore et al., 2012).
More recently, it has been shown that both 5-HT6Rs (Wang
et al., 2015) and 5-HT7Rs (Yang et al., 2012) were upregulated
in the human neocortex of PWE with refractory TLE. These
interesting findings call for more studies with 5-HT6R and
5-HT7R ligands.
Animal data
Acute seizure evocation with KA led to increases in hippocampal
5-HT tissue content and extracellular 5-HT levels (Alfaro-
Rodriguez et al., 2011; Tchekalarova et al., 2015a) while during
the spontaneous recurrent limbic seizures in the KA model
decreases in 5-HT content were found (Tchekalarova et al., 2011).
In another well-established post-SE rat model for focal epilepsy
using pilocarpine (i.e., a muscarinergic receptor agonist) as the
chemoconvulsant, 5-HT hippocampal content (Cavalheiro et al.,
1994) and hippocampal 5-HT levels (Meurs et al., 2008) were
increased during the acute seizure phase but not during the
following spontaneous recurrent seizure phase (Cavalheiro et al.,
1994; Szyndler et al., 2005). Comparing three acute limbic seizure
models, which differed only in the chemoconvulsant used to
evoke the seizures in rats, no straightforward correlation between
the seizure activity and increased hippocampal extracellular
5-HT concentrations could be found (Meurs et al., 2008).
Concerning the role of the somatodendritic 5-HT1A
autoreceptor in focal epilepsy, the majority of pharmacological
studies clearly highlight the anticonvulsant effects of 5-HT1AR
agonists against limbic seizures evoked in various rat models,
e.g., against pilocarpine-induced seizures (Clinckers et al., 2004;
Lopez-Meraz et al., 2005; Pericic et al., 2005; Orban et al., 2013),
as well as against status epilepticus evoked by lithium pilocarpine
(Yang et al., 2014).
Activation of the 5-HT2CRs do not appear to play a pivotal
role in focal epilepsy or on the contrary is proepileptic (Di
Giovanni and De Deurwaerdere, 2016). Indeed, 5-HT2CR
agonists with different pharmacological profiles such as
meta-chlorophenylpiperazine (mCPP) and lorcaserin, but not
RO60-0175, were able to stop the elongation of the electrically
triggered hippocampal maximal dentate gyrus activation in a
limbic seizure model in anesthetized rats, an effect that was not
blocked but rather potentiated by pre-treatment of SB 242084
(Orban et al., 2014), a selective 5-HT2CR antagonist. In addition,
5-HT3Rs display also no importance in focal hippocampal
seizures (Watanabe et al., 1998).
A selective 5-HT6R antagonist was able to attenuate
spontaneous recurrent seizures in the post-SE pilocarpine rat
model, and diminished hippocampal mechanistic target of
rapamycin (mTOR) activity, suggesting that 5-HT6Rs may
mediate limbic seizures via mTOR signaling (Wang et al.,
2015). Moreover, 5-HT6R expression was upregulated in the
hippocampus and neocortex of the pilocarpine-treated rats
(Wang et al., 2015), confirming the finding in PWE as described
above. There is one study showing that 5-HT7R antagonism
also diminished the number of limbic seizures in pilocarpine-
treated rats (Yang et al., 2012). More confirmatory results with
5-HT6R and 5-HT7R antagonists in focal epilepsy models might
be interesting to obtain.
In vitro data
Serotonin inhibited bicuculline (i.e., a GABAA receptor
antagonist)- and KA-evoked epileptiform activity in brain slices
via membrane hyperpolarization (Salgado and Alkadhi, 1995).
The use of a 5-HT3R agonist showed no effect on cortical
epileptiform activity (Bobula et al., 2001). In rat hippocampal
brain slices, 5-HT4R agonism aggravated population spikes,
evoked by electrical stimulation and spontaneous epileptiform
activity (Tokarski et al., 2002). The influence of many other 5-HT
receptor subtypes on epileptiform activity remains elusive.
Generalized Convulsive Seizures
Animal data
Hippocampal 5-HT1A and 5-HT1BR immunoreactivities were
decreased in the rat unilateral hypoxic-induced epilepsy model
(An and Kim, 2011). Anticonvulsant effects of 5-HT1AR agonists
have also been repeatedly reported in models for generalized
seizures, such as the pentylenetretrazole (PTZ, a prototypic
antagonist of GABAA receptors) model (Lopez-Meraz et al.,
2005), tonic-clonic seizures evoked by amygdala kindling (Lopez-
Meraz et al., 2005), and the picrotoxin (another typically used
antagonist of GABAA receptors) model (Pericˇic´ et al., 2005).
The seizure modulating roles of specific 5-HT1B, 5-HT1D,
and 5-HT1ERs are less studied, but anticonvulsant properties
upon 5-HT1B activation in the PTZ model were described
(Wesolowska et al., 2006).
Strong evidence for decreased excitability upon 5-HT2CR
activation was obtained from the 5-HT2CR knock out (KO)
mice that displayed a clear generalized epileptic phenotype
and exhibited an increased sensitivity to chemoconvulsant PTZ
(Tecott et al., 1995; Heisler et al., 1998).
The first report using a 5-HT3R ligand in relation to
epilepsy was described by Cutler and Piper (Cutler, 1990)
who showed that 5-HT3R antagonism had no effects upon
seizure susceptibility or severity in Mongolian gerbils. Unclear
effects of 5-HT3R antagonists were noted on audiogenic seizures
in Dilute Brown Non-Agouti (DBA)/2 mice (Semenova and
Ticku, 1992) and on alcohol withdrawal seizures (Kostowski
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et al., 1993; Grant et al., 1994). A 5-HT3R agonist facilitated
generalized seizure development in the well-characterized rat
amygdala kindling model (Wada et al., 1997). Despite all these
initial negative results, recent interest in the 5-HT3R subtype
emerged in the PTZ model for generalized seizures and in PTZ
kindling. Indeed, 5-HT3R agonism exhibited dose-dependent
anticonvulsant effects in the PTZ model (Li et al., 2014).
Moreover, the 5-HT3R subtype seems to play a prominent role
in mediating the anticonvulsant effects of various selective 5-HT
reuptake inhibitors in this classical PTZ model for generalized
epilepsy (Payandemehr et al., 2012; Alhaj et al., 2015).
PTZ-induced convulsive responses were aggravated in
5-HT4R KO mice (Compan et al., 2004). Potent and selective
5-HT6R antagonists displayed clear anticonvulsant effects in the
maximal electroshock test in rats (Routledge et al., 2000; Stean
et al., 2002; Hirst et al., 2006).
Some pharmacological studies with 5-HT7R antagonists
pointed to anticonvulsant effects in various rodent models. For
instance, antagonism of 5-HT7Rs protected DBA/2J mice against
audiogenic seizures (Bourson et al., 1997). Anticonvulsant effects
of 5-HT7R agonists were also described against picrotoxin-
evoked seizures in mice (Pericic and Svob Strac, 2007). In
line with these findings, constitutive deletion of the 5-HT7R
resulted in proconvulsant effects as the KO mice exhibited
decreased thresholds for electroshock-induced seizures and
decreased seizure thresholds for PTZ- and cocaine-induced
seizures (Witkin et al., 2007). More investigations are therefore
needed to clarify the exact role of the 5-HT7R in generalized
epilepsy.
Generalized Non-convulsive Seizures and Epilepsy
Syndromes
Human data
Insufficient human evidence on generalized non-convulsive
seizures and epilepsy syndromes exists so far. Treatment of amale
patient suffering from drug-resistant epilepsy, resulting from a
deleterious de novo sodium voltage-gated channel alpha subunit
2 (SCN2A), gene splice-site mutation, with the 5-HT precursor 5-
hydroxytryptophan, led to mild clinical improvement (Horvath
et al., 2016).
Animal data
Some typical 5-HT2CR agonists dose-dependently suppressed
absence seizures in the Genetic Absence Epilepsy Rats from
Strasbourg (GAERS), a well-established polygenic rat model of
absence epilepsy and non-convulsive seizures; these effects were
prevented when administering a selective 5-HT2CR antagonist,
indicating the potential of selective 5-HT2CR agonists as novel
anti-absence drugs (Venzi et al., 2016). Experiments on Wistar
Albino Glaxo rats from Rijswijk (WAG/Rij) rats, another
polygenic rat model of absence epilepsy, have found that mCPP
decreased spike-wave discharges (SWDs) cumulative duration
via the activation of 5-HT2CRs (Jakus et al., 2003). Strikingly,
while SB 242084 had no effect on SWDs when administered
on its own in WAG/Rij rats, (Jakus et al., 2003; Jakus and
Bagdy, 2011) it showed some anti-absence effects in GAERS.
The 5-HT2BR is less characterized and/or without effect on
the threshold for generalized seizures (Upton et al., 1998; Di
Giovanni and De Deurwaerdere, 2016). Antagonism of 5-HT7Rs
reduced spontaneous spike-wave discharges in the WAG/Rij rats
(Graf et al., 2004).
In vitro data
Sourbron et al. (2016) were able to demonstrate that selective
5-HT1D-, 5-HT1E-, 5-HT2A-, 5-HT2C-, and 5-HT7-R agonists
significantly decreased epileptiform activity in a homozygous
sodium voltage gated channel alpha subunit 1 (SCN1A) mutant
zebrafish model for Dravet syndrome (Sourbron et al., 2016).
Dopaminergic System in Epilepsy
The seizure modulating effects of DA have received a lot of
attention since the 1960s, so it is almost an impossible task
to review the abundant evidence to date. This section will
therefore summarize the most obvious findings and highlight a
few recent studies. For a more expanded review, we recommend
the fine manuscript by Bozzi and Borrelli (2013) who reviewed
the intracellular signaling pathways triggered by activation of
different DA receptors (DARs) in relation to their role in limbic
seizures and epileptogenesis (Bozzi and Borrelli, 2013).
For years, it has been known that innate deficiencies in DA
contributed to the seizure-prone states of some genetic rodent
models and therefore may be a predisposing factor for human
epilepsy (Starr, 1996). Generally, excitability is affected in a
biphasic fashion via DAergic actions: D1-like receptor activation
merely increases excitation while D2-like receptor activation
largely leads to anticonvulsant actions. The important role of
D2-like receptors in regulating brain excitability is clinically
supported by the well-known decrease in the seizure thresholds
in PWE treated with antipsychotic D2R antagonists. However,
information on selective D3R, D4R, and D5R modulating effects
on seizures are scarce.
Focal Seizures
Human data
In PWE suffering from TLE, alterations in the neocortical
DA content, D1-like and D2-like receptor expression, and DA
transporter (DAT) binding have been reported (Rocha et al.,
2012). Reduced D2R/D3R binding, sustained impairment of the
DAergic system, was demonstrated in extrastriatal and/or striatal
brain regions of PWE, specifically with TLE (Bernedo Paredes
et al., 2015).
Animal data
Similarly as described above for 5-HT, acute kainic acid-
induced seizures increased hippocampal DA tissue content
and extracellular DA levels, (Alfaro-Rodriguez et al., 2011;
Tchekalarova et al., 2015b) while during the spontaneous
recurrent limbic seizures in the kainic acid model, decreases
in DA content were found (Tchekalarova et al., 2011). In the
pilocarpine rat model, DA hippocampal content (Cavalheiro
et al., 1994) and hippocampal DA levels (Meurs et al., 2008) were
increased during the acute seizure phase. During the chronic
recurrent seizure phase in the pilocarpine model, hippocampal
DA content was elevated in one study (Cavalheiro et al., 1994)
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while no alterations were described in another study (Szyndler
et al., 2005). Interestingly, when comparing three acute limbic
seizure models, a direct relationship between the seizure activity
and increased hippocampal extracellular concentrations of DA
were established (Meurs et al., 2008).
In line with the majority of data described for generalized
seizures, D1-like receptor-activation results in seizure
enhancement in the limbic pilocarpine model (Barone
et al., 1990). Activation of hippocampal D2-like receptors,
leading to inhibition of adenylyl cyclase (AC) via Gi coupling,
consistently protected rodents against limbic motor seizures,
supporting seizure facilitation via D1R-mediated increases
in cyclic adenosine monophosphate (cAMP; Bozzi and
Borrelli, 2013). Moreover, the D2-like receptors seem to
play a pivotal role in the overall anticonvulsant effect of
hippocampal DA since a selective D2R antagonist abolished
DA-mediated anticonvulsant effects in the acute pilocarpine
limbic seizure model (Clinckers et al., 2004). Most interestingly,
D2-like receptor signaling in the hippocampus also leads to
glycogen synthase kinase 3β inhibition and hippocampal cell
survival following kainic acid administration (Dunleavy et al.,
2013).
In vitro data
Electrophysiological data demonstrated that DA can affect
hippocampal excitability in a biphasic fashion but the
predominant DA action was an D2-like receptor-mediated
inhibitory effect via hyperpolarization of the resting membrane
potential and a long-lasting increase in after-hypolarization
(Benardo and Prince, 1982). D4R KO mice displayed cortical
hyperexcitability, as measured with electrophysiological current
and voltage-clamp recordings, suggesting that D4R activation
can negatively modulate glutamate (GLU) activity in the frontal
cortex (Rubinstein et al., 2001). This is not unexpected from a
receptor from the D2-like receptor family that mainly exhibits
decreased excitation upon activation.
Generalized Convulsive Seizures
Human data
Patients with juvenile myoclonic epilepsy showed a reduction in
D2R/D3R binding restricted to the bilateral posterior putamen,
suggesting an alteration of the DAergic system within this region
(Landvogt et al., 2010).
Animal data
Repeated D1-like receptor activation results in generalized
seizures, disrupted hippocampal plasticity, and impaired long-
term recognition memory (Gangarossa et al., 2014). Initially,
the majority of results on D1-like receptor agonist effects on
behavioral seizure thresholds clearly indicated proconvulsant
effects (Starr, 1996). Nevertheless, recent reports showed that D1-
like receptor agonists, linked to stimulation of adenylate cyclase
(AC; but not phospholipase C, PLC), led to prominent behavioral
seizures in rodents, whereas D1-like receptor agonists, linked
to stimulation of phospholipase C (PLC, but not AC), did not
(O’sullivan et al., 2008). The D5R belongs to the D1-like receptor
family and upon its activation mainly increased excitation is
observed, although less prominent in comparison with D1R
activation and subsequent increases in cAMP (O’sullivan et al.,
2008).
The role of the D3R in seizure modulation appears to be
more complex. D3R KOs were less sensitive to picrotoxin-
induced clonic seizures and mortality suggesting proconvulsant
D3R-mediated signaling (Micale et al., 2009). On the other
hand, D3R-mediated agonist actions protected against acute and
cocaine-kindled seizures in mice and reduced lethal effects of
acute cocaine toxicity (Witkin et al., 2008). Most probably,
different D3R downstream signaling cascades in different
implicated brain regions may explain the contrasting results
(Bozzi and Borrelli, 2013); however more investigations are
required.
Generalized Non-convulsive Seizures and Epilepsy
Syndromes
Human data
The DA precursor L-3,4-dihydroxyphenylalanine (L-DOPA)
improved the clinical outcome of a male patient suffering
from intractable epileptic encephalopathy (Horvath et al., 2016),
again sustaining an overall anticonvulsant DA-mediated action.
Nevertheless, DA concentrations in media collected from neural
cultures, derived from induced pluripotent stem cells from a
patient with the Dravet syndrome, were higher than those from
wild-type neural cultures (Maeda et al., 2016).
Animal data
Activation of both D1-like and D2-like receptors showed anti-
absence effects (Deransart et al., 2000), probably by decreasing
GABAA receptor-mediated tonic inhibition (Yague et al., 2013)
that is altered in animal models of absence seizures (Cope et al.,
2009). Up-regulation of D3 (but not D1, D2, or D5) receptor
mRNA seems part of the epileptic phenotype in absence-epilepsy
prone rats (Deransart et al., 2001). The role of D1-like and D2-
like receptors in non-convulsive epilepsy is thus less clear-cut
in comparison with the data obtained in focal and generalized
seizure and epilepsy models.
Noradrenergic System in Epilepsy
The suggestion that NA may act as an anticonvulsant was posed
over 60 years ago (Chen et al., 1954). Subsequent experimental
studies provided firm evidence that the noradrenergic system
modifies seizure activity. Nowadays, vagus nerve stimulation
(VNS) is an adjunctive treatment for resistant epilepsy and
depression (Panebianco et al., 2016).
Focal Seizures
Human data
In this context, the receptor-binding assays with prazosin as a
ligand, performed on isolated cortical cell membranes from 10
PWE subjected to temporal lobectomy due to intractable partial
epilepsy, showed a reduced density of α1 adrenoceptor (AR)
in the sites of the epileptic foci with no change in affinity. It
was concluded that the lower receptor density may result in
noradrenergic hyposensitivity that could contribute to a localized
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diminution in inhibitory mechanisms in epileptic foci (Briere
et al., 1986).
Animal data
Likewise, VNS is an effective adjunctive treatment for medically
refractory epilepsy, and was found to produce its anticonvulsive
effect by increasing NA levels in the hippocampus that is critically
involved in the generation of limbic seizures (Raedt et al.,
2011). The anticonvulsant action of VNS on pilocarpine-induced
seizures in rats can be abolished by the blockade of hippocampal
α2-AR, indicating a strong causal link between the seizure-
suppressing effect of VNS and hippocampal noradrenergic
signaling (Raedt et al., 2011). Interestingly, combined but not
separate α2- and β2-AR stimulation inhibited limbic seizures
induced by pilocarpine infusion in the hippocampus of rats. On
the other hand, α1A-AR stimulation and α1D-AR antagonism
alone also inhibited seizures associated with respectively
significant hippocampal GABA increases and GLU decreases
(Clinckers et al., 2010).
In vitro data
NA has demonstrated both proconvulsant and antiepileptic
properties; however, the specific pharmacology of these actions
has not been clearly established. For instance, under conditions
of impaired GABAergic inhibition, the excitatory and inhibitory
effects of NA on hippocampal CA3 epileptiform activity are
mediated primarily via β- and α2-ARs respectively. Moreover,
the NA antiepileptic effect in CA3 epileptiform in vitro is not
dependent on the increase in GABAergic function (Jurgens et al.,
2005) but is due to the activation of the α2-AR on presynaptic
glutamatergic terminals of the recurrent axon collaterals of the
CA3 pyramidal neurons (Jurgens et al., 2007). While the α1-AR
antagonists prazosin and terazosin had no effect on hippocampal
CA3 epileptiform activity in slice with GABA system blocked,
(Jurgens et al., 2005) there is in vitro evidence showing that α1-AR
subtype activation was able to release GABA and somatostatin
at the single cell level. This suggests that α1-AR activation may
also represent one mechanism by which NA exerts anti-epileptic
effects within the hippocampus.
Generalized Convulsive Seizures
Human data
NA may have proconvulsant and anticonvulsant properties
under certain conditions; activated noradrenergic transmission
could be an etiological factor in some epilepsies. The available
clinical data on the subject (NA boosting antidepressants, α2
AR agonists, pheophromocytoma, etc.) are discussed in detail
by Fitzgerald (Fitzgerald, 2010). It has been shown that co-
administration of β-ARs ligands with conventional AEDs, i.e.,
diazepam, phenobarbital, lamotrigine, valproate, enhance the
anticonvulsive efficacy of the latter ones (De Sarro et al., 2002;
Fischer, 2002; Luchowska et al., 2002).
Animal data
It has been shown that the animals treated with the
monoaminergic toxin 6-hydroxydopamine (6-OHDA)
or the noradrenergic toxin N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine (DSP4), as well as DA beta-hydroxylase
(DBH) KO mice that lack NA, expressed increased susceptibility
to convulsing stimuli (Bortolotto and Cavalheiro, 1986; McIntyre
and Edson, 1989) while, on the contrary, the stimulation of
the locus coeruleus in the same animals consistently reduced
it (Libet et al., 1977; Weiss et al., 1990). Further confirmation
of inhibitory effects of NA on epileptogenesis was obtained by
studying the genetic epilepsy-prone rat (GEPR) model (Yan
et al., 1993, 1998). With regard to a question related to the
receptors involved, the studies yielded conflicting results; the
same ligands—agonists or antagonists, could have proconvulsant
or anticonvulsant effects, depending on the animal species, the
strain, the model of epilepsy employed (for refs see Fitzgerald,
2010) and also receptor location, as in case of α2-AR (Szot
et al., 2004). Specifically, in flurothyl model of generalized
convulsive seizures, it has been suggested that presynaptic
α2-AR is responsible for the proconvulsant effect of α2-AR
agonists, while the postsynaptic α2-AR is responsible for the
anticonvulsant effect of α2-AR agonists (Szot et al., 2004). That
α2-ARs mediate anticonvulsive effects is supported also by the
observation that D79N mice which carry a point mutation
in the locus of α2-AR develop amygdala kindling very easily
(Janumpalli et al., 1998). Fewer studies concerned with α1-AR
have been conducted. In DBH KO mice, pre-treatment with
α1-AR agonist protected these mice against PTZ induced
seizures while α1-AR antagonist exacerbated PTZ induced
seizures in the control mice (Weinshenker et al., 2001b). As to
β-ARs, the anticonvulsive activity of propranolol, a non-selective
antagonist, has been demonstrated in a variety of animal
models of generalized tonic-clonic seizures. Propranolol reduced
seizures induced in mice by lidocaine, PTZ, strychnine, low
frequency, and maximal electroshock (Saelens et al., 1977; Akkan
et al., 1989; Fischer, 2002) as well as by sound in DBA/2 mice
(Anlezark et al., 1979; De Sarro et al., 2002), and increased the
threshold for lidocaine-induced convulsions in awake animals
(Nakamura et al., 2008). Other beta blockers that showed
some protective effects include metoprolol, for instance against
audio seizures (De Sarro et al., 2002). On the other hand, the
anticonvulsant effects of higher doses of clenbuterol against
generalized tonic-clonic seizures has also been demonstrated in
a couple of used tests (Fischer et al., 2001). Pre-treatment with
α1-AR or β2-AR, but not α2-AR or β1-AR agonist significantly
protected against PTZ-induced seizures in DBH−/− mice.
Therefore, activation of the α1-AR is primarily responsible for
the anticonvulsant activity of endogenous NA in the murine PTZ
model of epilepsy. Endogenous NA probably does not activate
the β2-AR under these conditions, but exogenous activation of
the β2-AR produces an anticonvulsant effect (Weinshenker et al.,
2001a).
Generalized Non-convulsive Seizures and Epilepsy
Syndromes
Animal data
Further confirmation of inhibitory effects of NA on
epileptogenesis was obtained in GAERS (Micheletti et al.,
1987). It has also been shown that various antiepileptic drugs,
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i.e., carbamazepine, have a modulatory, activating effect on NA
system (Olpe and Jones, 1983; Post, 1988).
Melatonin System in Epilepsy
Melatonin (MT), N-acetyl-5-methoxytryptamine, is a major
hormone of the pineal gland chiefly involved in circadian and
seasonal rhythm regulations. Beyond that, it exerts a multitude
of anti-excitatory and sedating effects that have been reviewed
recently (Reiter et al., 2010; Hardeland et al., 2011). The
majority of data indicates anticonvulsant properties of MT when




In an early electrophysiological study, epileptiform field
potentials were elicited by omission of Mg2+ from the
superfusate and recorded from layers II–V of human temporal
neocortical slices cut from tissue resected for surgical treatment
of epilepsy. The frequency of occurrence of epileptiform field




Clinical studies on a group of 54 children have demonstrated
that during a convulsive crisis, the MT concentration in
blood, as measured in patient’s serum, significantly peaked but
normalized within 1 h. The MT production stimulated by the
convulsive crisis may be part of the response of the organism
counteracting the seizures effects (Molina-Carballo et al., 2007).
Nevertheless, in other studies no changes in serum or salivary
MT concentrations were found after epileptic seizures (Rao
et al., 1989; Motta et al., 2014). Clinical reports have shown
the beneficial effect of MT treatment on seizure activity during
the day and night (Goldberg and Spealman, 1983; Peled et al.,
2001) in patients with intractable epilepsy. Systematic review of
all so far published clinical data on MT in relation to epilepsy,
including therapeutic use of MT, lead to the conclusion that there
is no marked improvement or worsening of seizures with MT
(Jain and Besag, 2013) or its use as add-on treatment (Brigo
and Igwe, 2016). Only large randomized double blind placebo-
controlled trials could give the final answer. In addition, it has
been recently suggested that melatonergic drugs may be effective
in treating comorbid depression in PWE (Tchekalarova et al.,
2015b)
Animal data
The anticonvulsant activity exerted by MT seen in animal
models of epilepsy (Golombek et al., 1992, 1996; Cardinali et al.,
2008; Solmaz et al., 2009) has been suggested to be executed
via increasing the activity of GABAergic system (Golombek
et al., 1996). A selective MT1/MT2R agonist mimicked the MT
effects in rat rapid kindling model and in the spontaneously
epileptic mice lacking voltage-gated Kv1.1 channels (Kcna1-
null mice; Fenoglio-Simeone et al., 2009). Beneficial actions of
MT in epilepsy have also been attributed to its free radical
scavenging properties (Mohanan and Yamamoto, 2002). MT has
been reported to have an anticonvulsant action in many models
of acute seizures, such as those produced by the administration
of PTZ, picrotoxin, bicuculline, pilocarpine, l-cysteine, kainate,
3-mercaptopropionic acid, quinolinate, GLU, strychnine, N-
methyl-d-aspartate (NMDA), or penicillin, as well as in the
maximal electroshock seizure (MES) test in rats, mice, gerbils,
and hamsters (see Banach et al., 2011). MT treatment during
epileptogenesis can have beneficial effects against the deleterious
consequences of SE in the KA model of TLE. Melatonin
chronic treatment increased the seizure-latent period, decreased
the frequency of spontaneous recurrent seizures (SRSs), and
attenuated the circadian rhythm of seizure activity (Petkova
et al., 2014; Tchekalarova et al., 2015b). These findings are in
agreement with the earlier evidence that pinealectomy facilitates
the epileptogenic process that follows the long-lasting SE.
This facilitation can be partially reverted by the simultaneous
administration of MT (De Lima et al., 2005). Agomelatine is a
novel antidepressant agent, which is structurally homologous to
MT. It is a potent MT1 and MT2 MTR agonist as well as a 5-
HT2CR receptor antagonist (Millan et al., 2003). It was recently
approved as an antidepressant medication with comparable
efficacy to classical antidepressant drugs (Sansone and Sansone,
2011). Agomelatine has anticonvulsant activity shown in PTZ- or
pilocarpine-induced seizure models due to its combined action at
MT1/2 and 5-HT2CRs (Aguiar et al., 2012).
Generalized Non-convulsive Seizures and Epilepsy
Syndromes
Animal data
It has been shown that subchronic and systemic administration of
agomelatine and MT displayed considerable antiepileptic effects
on absence seizures in WAG/Rij rats (Hatice et al., 2015).
Agomelatine seems to be recommendable as a potential drug
for absence epilepsy and many other complications such as
depression and sleep disorders associated with epilepsy.
Histaminergic System in Epilepsy
The CNS histaminergic system is involved in variety of
physiological and behavioral functions among them sleep-wake
cycle, appetite control, cognitive functions, neuroendocrine
functions, locomotor activity, emotion, and stress behavior.
Histamine is formed locally in the CNS; the synthesizing
enzyme histidine decarboxylase operates under subsaturating
concentration of L-histidine. An increase in the substrate
supply results in enhancement of cerebral histamine pool. Of
the four histamine receptors (HRs), in the cerebral tissues
H1–H3Rs are undoubtedly present. While H1 and H2Rs are
located postsynaptically, the H3 ones are presynaptic auto-
or heteroreceptors, controlling the release and synthesis of
histamine, and modulating release of other neurotransmitters,
e.g., acetylcholine, DA, NA, 5-HT, glutamate, and GABA
(Schwartz et al., 1991; Haas and Panula, 2003). The involvement
of cerebral histamine in regulation of seizure susceptibility
is sufficiently documented by both clinical and experimental
studies, which strongly point to histamine as an anticonvulsant.
The antiepileptic activity seems to be mediated by H1 and H3Rs.
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Focal Seizures
Animal data
In a comprehensive study on amygdala kindled seizures in
rats, convincing evidence for the suppressive role of central
histamine in epilepsy was provided (Kamei, 2001). In the
amygdala of kindled rats, a significant decrease of histamine
concentrations was disclosed. Exogenous histamine administered
to kindled animals elicited the seizure inhibiting effect that was
mimicked by H1R agonists but not H2R agonists. Moreover,
when administered repeatedly to rats, L-histidine retarded
development of amygdala kindling (Kamei et al., 1998).
Histidine and metoprine also inhibited seizures, and both
treatments were associated with enhanced histamine levels in
cerebral cortex, hippocampus, hypothalamus, and amygdala.
H3R antagonists evoked an antiepileptic effect, which was
prevented by pretreatment with an H3R agonist and was sensitive
to H1R antagonists. As shown by others (Jin et al., 2005)
amygdala kindled seizure inhibition could also be achieved by
administration of dipeptide carnosine (beta-alanyl-L-histidine).
The antiepileptic effect was antagonized by H1R blockers of
the first generation (pyrilamine, diphenhydramine), indicating
histamine participation.
Generalized Convulsive Seizures
Accordingly, manipulations of the endogenous histamine level
that resulted in its increase (stimulation of synthesis, inhibition
of degradation) was invariably associated with the inhibition of
convulsions or increased threshold for seizure induction, the
opposite being true for procedures that caused either decrease
of brain histamine concentration or blocked histamine signaling
via H1 or activated H3Rs. For instance, metoprine, an inhibitor of
histamine catabolizing enzyme, histamine N-methyl transferase,
inhibited electroshock seizures (Tuomisto and Tacke, 1986).
Animal data
Metoprine inhibited seizures evoked by amygdala kindling in rats
(Kamei et al., 1998; Kamei, 2001), as well as reduced audiogenic
convulsions in genetically audiogenic seizure sensitive rats
(Tuomisto et al., 1987). Likewise, L-histidine inhibited amygdala
kindled seizures (Kamei et al., 1998) as well as PTZ-induced
seizures in rats (Chen et al., 2002), an effect potentiated
by H3R antagonist, thioperamide, and antagonized by α-
fluoromethylhistidine (inhibitor of histidine decarboxylase) as
well as by pyrilamine, H1R antagonist (Chen et al., 2002).
In audiogenic epilepsy prone Krushinski–Molodkina rats, as
opposed to epilepsy resistant Wistar rats, brain histamine
concentrations are significantly lower (Onodera et al., 1992).
In different animal models of epilepsy, imidazole and non-
imidazole H3R antagonists facilitating the release of histamine
have proven to be beneficial (Yokoyama et al., 1993; Kakinoki
et al., 1998; Kamei, 2001). Pitolisant, an H3R antagonist, showed
excellent antiepileptic activity in animal models of seizure,
predictive for generalized, MES test in mice (Sadek et al., 2014).
Clinical data
Interestingly, children with febrile seizures showed significantly
lower histamine concentrations in cerebrospinal fluid than febrile
children without seizures. Based on these findings, the suggestion
was made that brain histaminergic system may be involved in
inhibiting seizures associated with febrile illnesses in childhood
(Kiviranta et al., 1995). The clinical data amply documented
proconvulsant effects of H1R antagonists administered in
clinically relevant doses (Churchill and Gammon, 1949;
Yokoyama et al., 1993; Takano et al., 2010; Miyata et al., 2011;
Zolaly, 2012). Therefore, centrally acting H1R antagonists
which may increase seizure susceptibility in patients with febrile
seizures are neither recommended to these patients nor to PWE.
Also, they should be avoided in young infants, more sensitive
to the drugs that could potentially disturb the anticonvulsive
central histaminergic system. The potential antiseizure activity of
pitolisant, a non-imidazole H3R inverse agonist, was examined
in 14 photosensitive adults using the photosensitivity standard
model and employing 20/40/60mg dose. Significant suppression
of generalized epileptiform discharges was observed in the
majority of the PWE (Kasteleijn-Nolst Trenite et al., 2013;
Bialer et al., 2015). Unfortunately, a recent multicenter, national,
pragmatic, noncomparative, open-label, exploratory phase II
trial reported there was no clinical effects of pitolisant in human
epilepsy, in spite of the existing promising animal data (Collart
Dutilleul et al., 2016).
Generalized Non-convulsive Seizures and Epilepsy
Syndromes
Animal data
WAG/Rij strain showed an increase in the density of H1R binding
in the frontal motor cortex and interposed nucleus of cerebellum
and a decrease in the substantia nigra compacta compared to
the non-epileptic control group (Midzyanovskaya et al., 2016).
Taking into account the bidirectional effect of the H1R antagonist
pyrilamine on SWDs in WAG/Rij rats (Midzyanovskaya et al.,
2005), it may be speculated that histamine modulates different
areas involved in opposite absence seizure modulation.
MONOAMINES IN EPILEPSY: GENETIC
EVIDENCE
Genetic Animal Studies
Genetics of Serotonergic System
As shown inTable 1, various KO animal studies have investigated
the contribution of the serotonergic system in the neurobiology
of epilepsy (Theodore, 2003; Bagdy et al., 2007).
Some of the first such studies involved GEPRs, which
displayed deficits in serotonergic system (Dailey et al., 1989).
Specifically, these rats had lower brain 5-HT concentration,
synaptosomal 5-HT uptake, and tryptophan hydroxylase activity
in regions of forebrain and brainstem (Statnick et al., 1996).
Moreover, various studies demonstrated reduced hippocampal
5-HTR density in the GEPRs (Dailey et al., 1992; Statnick
et al., 1996; Salgado-Commissariat and Alkadhi, 1997) suggesting
the critical importance of serotonergic activity in seizure
regulation (Jobe et al., 1999). In line with these findings,
results obtained on GEPRs also suggest that antiepileptic
drugs such as carbamazepine and valproate increase 5-HT
concentrations as a part of their mechanism of action (Yan
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TABLE 1 | Animal studies investigating the involvement of monoamine systems in epilepsy.
Animal model Findings References
SEROTONERGIC SYSTEM
Genetically epilepsy-prone rats Deficits in serotonergic and noradrenergic systems Dailey et al., 1989
Lower brain 5-HT concentration, synaptosomal 5-HT uptake, and
tryptophan hydroxylase activity in regions of forebrain and brainstem
Statnick et al., 1996




Antiepileptic drugs such as carbamazepine and valproate increase 5-HT
concentrations
Yan et al., 1992; Dailey
et al., 1997
Genetic mutant mice lacking 5-HT1A receptors Increased seizure susceptibility Sarnyai et al., 2000
Genetic mutant mice lacking 5-HT2C receptors Increased seizure susceptibility Tecott et al., 1995; Brennan
et al., 1997
C57BL/6J (6J) and C57BL/6ByJ (6ByJ) mice 5-HT2 receptors mediate genetic sensitivity to cocaine-induced convulsions O’dell et al., 2000
DOPAMINERGIC AND NORADRENERGIC SYSTEMS
Genetic Absence Epilepsy Rats from Strasbourg Reduced D2 receptor binding sites in the caudate–putamen and CA3
hippocampal region
Jones et al., 2010
Wistar Albino Glaxo rats from Rijswijk Reduced D2 receptor binding sites in the caudate–putamen and CA3
hippocampal region
Birioukova et al., 2005
D2 receptor knockout (D2R−/−) mice Increased susceptibility to seizures induced by kainic acid Bozzi et al., 2000; Tripathi
et al., 2010
Increased susceptibility to seizures induced by pilocarpine Bozzi and Borrelli, 2002,
2006
CA3 hippocampal apoptotic cell death Bozzi et al., 2000; Bozzi and
Borrelli, 2006; Tripathi et al.,
2010
Congenic D4 “knockout” mice D4 receptors in the interaction with D1 receptors positively regulate D1
receptor-mediated seizures
O’sullivan et al., 2006
D4 receptor knockout (D4R−/−) mice Spontaneous synaptic activity and epileptic discharges induced by
4-aminopyridine or bicuculline increased in cortical slices
Rubinstein et al., 2001
D1 and D5 receptor knockout mice D1 and D5 receptor-dependent induction of seizures O’sullivan et al., 2008
DBH (DBH−/− mice) knock-out mice Mice susceptible to of pentylenetetrazole-induced seizures, activation of the
a1AR is responsible for the anticonvulsant activity of endogenous
noradrenaline; noradrenergic agonists have protective effects against
seizures
Weinshenker et al., 2001a
HISTAMINERGIC SYSTEM
H1 receptor gene knockout, histidine decarboxylase
deficient and mast cell-deficient mice
Faster development of pentylenetetrazole-induced seizures and increased
histamine content in diencephalon
Chen et al., 2003
EL mice-genetic model of human temporal lobe
epilepsy
Inhibitory actions of the histaminergic neurons on the epileptogenesis;
Pretreatment with histidine and metoprine delayed, while H1 blockade
speed up the time of seizure onset
Yawata et al., 2004
et al., 1992; Dailey et al., 1997). In addition to rats, genetic
mutant mice lacking 5-HT1ARs (Sarnyai et al., 2000) or 5-
HT2CRs (Tecott et al., 1995; Brennan et al., 1997) displayed
increased seizure susceptibility, suggesting the involvement
of these receptors in the regulation of neuronal excitability.
In addition, 5-HT2CRs have been suggested to mediate
genetic sensitivity to cocaine-induced convulsions (O’dell et al.,
2000).
Genetics of Dopaminergic and Noradrenergic
Systems
Genetically altered rats and mice were used to provide an
insight into the role of the DAergic system in the epileptogenesis
(Table 1). DA D2R binding sites were found to be reduced
in the caudate-putamen and CA3 hippocampal region of
GAERS (Jones et al., 2010) and WAG/Rij rats (Birioukova
et al., 2005). In mice, inactivation of the D2R gene and
consequently impaired D2R-mediated signaling resulted in more
severe seizures. Namely, D2R KO mice showed an increased
susceptibility to seizures induced by kainic acid (Bozzi et al.,
2000) and pilocarpine (Bozzi and Borrelli, 2002, 2006). In
these mice, CA3 hippocampal apoptotic cell death was observed
(Bozzi et al., 2000; Bozzi and Borrelli, 2006; Tripathi et al.,
2010), suggesting that D2R activation may be neuroprotective.
Further studies on DAR KO mice investigated the intracellular
pathways activated by different DARs in response to seizures
(Bozzi et al., 2000; Rubinstein et al., 2001; Bozzi and Borrelli,
2002; O’sullivan et al., 2008; Tripathi et al., 2010; Dunleavy et al.,
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2013). These experiments also established the role of D1 and
D5Rs in the regulation of synaptic activity (O’sullivan et al.,
2008). Moreover, spontaneous synaptic activity and epileptic
discharges induced by 4-aminopyridine or bicuculline were
increased in cortical slices from D4R KO mice (Rubinstein
et al., 2001). It has been suggested that D4Rs in interaction with
D1Rs positively regulate D1R-mediated seizures (O’sullivan et al.,
2006).
In the evaluation of the contribution of NA to neuronal
excitability (Table 1), an animal model of DBH KO mice was
used (Weinshenker et al., 2001b). These mice lacking NA
were susceptible to seizures, and noradrenergic agonists
showed protective effects against seizures. Endogenous
NA had anticonvulsant effects and was confirmed to
represent a potent endogenous inhibitor of neuronal
excitability, and these results suggest that future strategies
should be focused on noradrenergic drugs to treat epilepsy
(Weinshenker et al., 2001b).
Genetics of Histaminergic System
As demonstrated in Table 1, histaminergic neurons have also
been postulated to have important role in the inhibition of
convulsions and seizures (Yawata et al., 2004), since it has
been shown that increased H concentrations suppressed seizures
and presumably have neuroprotective properties (Bhowmik
et al., 2012). In an animal model of epilepsy with PTZ-
induced chemical kindling, behavioral, and neurochemical
characteristics were examined in various strains of mutant
mice (in H1R KO mice, histidine decarboxylase deficient, and
mast cell-deficient mice) compared to their wild type mice
(Lai et al., 2003). Mutant mice displayed faster development
of seizures and increased histamine content in diencephalon
compared to the corresponding wild type mice, suggesting
that histamine has protective anticonvulsive effects on seizures
achieved via H1Rs (Lai et al., 2003). In another animal
model, in EL mouse (genetic model of human temporal
lobe epilepsy), inhibitory actions of the histaminergic neurons
on the epileptogenesis were reported (Yawata et al., 2004).
In these mice, pretreatment with histidine, a precursor of
histamine, and with metoprine, an inhibitor of the histamine
N-methyltransferase, delayed the time of onset of the seizures,
while H1R blockade with antagonist speed it up (Yawata et al.,
2004).
Genetic Human Studies
Genetics of Serotonergic System
As shown in Table 2, the genetic background regarding
serotonergic system in epileptogenesis has been most frequently
investigated using the association between SERT (or 5-HTT)
gene variants and epilepsy. Genetic mutations in the 5-HTT
gene influence 5-HTT expression and change extracellular 5-HT
levels, therefore increasing susceptibility to seizures (Ottman
and Risch, 2012; Salzmann and Malafosse, 2012). One of the
most studied polymorphisms in this gene is a variable number
of tandem repeats (5-HTTVNTR) polymorphism, located in
the second intron, with a repetition unit containing 17 bp.
There are three alleles of 5-HTTVNTR that contain 9, 10, or
12 repetitions. Less efficient transcriptional genotypes (10/10)
of the 5-HTTVNTR were found more frequently in PWE
with juvenile myoclonic epilepsy (JME) compared to control
subjects of Egyptian origin (Esmail et al., 2015). The similar
result, with the higher frequency of the 10-repeat allele of the
5-HTTVNTR in PWE with TLE in comparison to controls,
was observed in Brazilian subjects (Schenkel et al., 2011). In
Han Chinese population, one study reported higher frequency
of the 10-repeat allele (Li et al., 2012), whereas the other
found higher frequencies of transcriptionally more efficient
12/12 genotype and allele 12 (Che et al., 2010), in the PWE
with TLE than in normal controls. On the other hand,
Italian PWE with TLE showed lower frequencies of the 10
repeat of the 5-HTTVNTR in comparison to control subjects
(Manna et al., 2007), whereas results obtained on Croatian
subjects demonstrated lack of association of 5-HTTVNTR
polymorphismwith TLE (Stefulj et al., 2010). In subjects suffering
from mesial TLE with hippocampal sclerosis (MTE-HS), the
treatment response to antiepileptic drug was evaluated: 12/12
genotype of 5-HTTVNTR polymorphism was found to be
associated with significantly increased risk for a nonresponse to
medical treatment compared to carriers of the 10-repeat allele
(Kauffman et al., 2009). Moreover, PWE with TLE carrying the
combination of transcriptionally more efficient 5-HTTVNTR
(12/12) genotype and L/L genotype of another common
5-HTT polymorphism, 5-HT-transporter-linked polymorphic
region (5-HTTLPR), displayed poorer treatment response to
antiepileptic medication therapy (Hecimovic et al., 2010).
5-HTTLPR is a biallelic polymorphism located in the 5′
regulatory region of 5-HTT gene. 5-HTTLPR short (S) allele
has been associated with lower transcriptional efficiency of
this gene and lower 5-HT uptake activity, in comparison to
the long (L) allele (Lesch et al., 1994; Heils et al., 1996).
Although the homozygous S genotype was found to significantly
increase risk of developing alcohol withdrawal seizures and
delirium (Sander et al., 1997), no significant differences were
observed in the frequencies of 5-HTTLPR genotypes and alleles
in PWE with TLE and normal controls in Chinese Han (Che
et al., 2010) and Croatian (Stefulj et al., 2010) populations,
as well as in the PWE suffering from IGE (Sander et al.,
2000). In addition, a meta-analysis including 5-HTTVNTR and
5-HTTLPR polymorphisms, suggested that 5-HTT gene may not
be the primary determinant of epilepsy susceptibility, but in
the interaction with other genes involved in different signaling
pathways, it might participate in epileptogenesis (Yang et al.,
2013).
Studies investigating the role of 5-HTR gene variants in
susceptibility to seizure generation demonstrated no association
of Cys23Ser polymorphism located in the gene HTR2C with
IGE or alcohol withdrawal seizures (Samochowiec et al., 1999;
Stefulj et al., 2010). Moreover, genetic variants of the C1019G
polymorphism in the HTR1A gene also displayed similar
distribution among PWE with TLE and control subjects (Stefulj
et al., 2010). However, the 5-HT1AR mRNA expression was
found to be higher in hippocampal tissue of PWE with TLE
homozygous for the C-allele of rs6295 polymorphism, located in
the promoter region of the human HTR1A gene, as compared to
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TABLE 2 | Human studies investigating the involvement of monoamine systems in epilepsy.
Human study Findings References
SEROTONERGIC SYSTEM
Juvenile myoclonic epilepsy (JME) Less efficient transcriptional genotypes (10/10) of the 5-HTTVNTR
polymorphism were more frequent in patients with JME
Esmail et al., 2015
Temporal lobe epilepsy (TLE) Higher frequency of the 10-repeat allele of the 5-HTTVNTR polymorphism in
patients with TLE in comparison to controls
Schenkel et al., 2011
Higher frequency of the 10-repeat allele of the 5-HTTVNTR polymorphism in
patients with TLE than in normal controls
Li et al., 2012
Higher frequencies of transcriptionally more efficient 12/12 genotype and
allele 12 of the 5-HTTVNTR polymorphism in patients with TLE than in
normal controls
Che et al., 2010
Lower frequencies of the 10 repeat of the 5-HTTVNTR polymorphism in
comparison to control subjects
Manna et al., 2007
Lack of association of 5-HTTVNTR polymorphism with TLE Stefulj et al., 2010
TLE patients carrying the combination of transcriptionally more efficient
5-HTTVNTR (12/12) genotype and L/L genotype of 5-HTTLPR
polymorphism had poorer treatment response to antiepileptic therapy
Hecimovic et al., 2010
Mesial temporal lobe epilepsy with hippocampal
sclerosis (MTE-HS)
12/12 genotype of 5-HTTVNTR polymorphism associated with increased
risk for a nonresponse to medical treatment compared to carriers of the
10-repeat allele
Kauffman et al., 2009
Alcohol withdrawal seizures Homozygous S genotype of 5-HTTLPR polymorphism significantly increase
risk to develop alcohol withdrawal seizures
Sander et al., 1997
Temporal lobe epilepsy (TLE) Lack of association of 5-HTTLPR polymorphism with TLE Che et al., 2010; Stefulj
et al., 2010
Idiopathic generalized epilepsy Lack of association of 5-HTTLPR polymorphism with IGE Sander et al., 2000
Idiopathic generalized epilepsy or alcohol
withdrawal seizures
Lack of association of Cys23Ser polymorphism of HTR2C with IGE or
alcohol withdrawal seizures
Samochowiec et al., 1999;
Stefulj et al., 2010
Temporal lobe epilepsy (TLE) Lack of association of C1019G polymorphism of HTR1A with TLE Stefulj et al., 2010
Higher expression of 5-HT1A receptor mRNA expression in hippocampal
tissue of TLE patients homozygous for the C-allele of rs6295 polymorphism
in HTR1A, as compared to patients with the GG-genotype
Pernhorst et al., 2013
Marginally increased frequency of 861G allele of the G861C polymorphism
in 5-HT1B receptor gene in the patients with TLE
Stefulj et al., 2010
T variant of 1354CT polymorphism in HTR2A may influence an earlier age of
onset of TLE
Manna et al., 2012
DOPAMINERGIC AND NORADRENERGIC SYSTEMS
Epilepsy and antiepileptic drug response Lack of association between DBH C-1021T polymorphism and epilepsy,
several epilepsy subtypes, or response to antiepileptic drugs
Depondt et al., 2004
Effects of antiepileptic drug Patients with genetic variants of DBH rs1611115, COMT rs4680 and
dopamine receptor D2 rs1800497 polymorphisms, associated with
decreased dopaminergic activity, have higher susceptibility to negative
psychotropic effects of levetiracetam
Helmstaedter et al., 2013
Idiopathic generalized epilepsy (Dailey et al.) Higher frequency of the 9-copy allele of DAT polymorphism was observed in
IGE and IAE patients compared to the control group
Sander et al., 2000
Idiopathic absence epilepsy (IAE)
ENZYMES INVOLVED IN THE MONOAMINE SYNTHESIS AND METABOLISM
Neurological syndrome with learning disabilities,
epilepsy, and psychiatric symptoms
Mutation-induced deficiency of the 6 pyruvoyl tetrahydropterin synthase,
necessary for normal function of tyrosine and tryptophan hydroxylases
Ng et al., 2015
Neurological syndrome with mental retardation and
epilepsy
Inherited duplication of Xp11.3, including MAOA and MAOB genes Tzschach et al., 2008;
Klitten et al., 2011
Inherited deletion of Xp11.3, including MAOA and MAOB genes Whibley et al., 2010
Idiopathic generalized epilepsies (Dailey et al.) Lack of association between the MAOA-uVNTR polymorphism and different
IGE subtypes
Haug et al., 2000
Temporal lobe epilepsy (TLE) Lack of association between the MAOA-uVNTR polymorphism and TLE Stefulj et al., 2010
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PWEwith the GG-genotype (Pernhorst et al., 2013). On the other
hand, the frequency of 861G allele of the G861C polymorphism
in the HTR1B gene was found to be marginally increased in
the PWE with TLE, implicating this allele in the susceptibility
to TLE (Stefulj et al., 2010). The 861G allele has been linked
with fewer 5-HT1BRs in the human brain, in comparison to
861C allele (Huang et al., 1999). In addition, Manna et al. (2012)
demonstrated that the T variant of 1354CT polymorphism in
HTR2A gene may be implicated in an earlier age of onset of TLE
(Manna et al., 2012).
Genetics of Dopaminergic and Noradrenergic
Systems
DBH, another enzyme involved in conversion of DA to NA,
is important for the maintenance of central DA and NA
concentrations (Table 2). It is presumed that endogenous NA
has an antiepileptic effect, especially in limbic regions, and
regulates seizure threshold (Giorgi et al., 2004). Plasma DBH
was shown to decrease during epileptic seizures (Miras-Portuga
et al., 1975). The functional polymorphism in the DBH gene, the
DBH (rs1611115 or C-970T or DBH C-1021T) polymorphism
affects DBH activity and is responsible for almost 50% of the
plasma DBH variations. However, there were no significant
differences in the frequency of the TT, TC, and CC genotypes
in the DBH C-1021T between large numbers of PWE and
control subjects (Depondt et al., 2004). Depondt and colleagues
detected no significant association between DBH C-1021T
polymorphism and epilepsy, several epilepsy subtypes, or
response to antiepileptic drugs, implying that this polymorphism
does not contribute to epilepsy (Depondt et al., 2004). On the
other hand, epileptic PWE carrying genetic variants of rs1611115
polymorphism in DBH gene, rs4680 polymorphism located in
the gene coding for catechol-O-methyltransferase (COMT) and
rs1800497 polymorphism in DA D2R gene, all genetic variants
associated with decreased DAergic activity, showed a higher
susceptibility to negative psychotropic effects of the antiepileptic
drug levetiracetam (Helmstaedter et al., 2013). These findings
suggested that decreased DAergic transmission in PWE may
worsen the outcome and adverse effects of treatment with specific
AEDs.
Genetic studies investigating other components of DAergic
system in epilepsy, include polymorphisms in the human DAT
gene, which may explain inter-individual differences in the
density or affinity of DAT (Table 2). The study of Sander
et al. (2000) reported the association of the 40 bp repeats
polymorphism in the 3′ untranslated region of the DAT gene
with IGE, and especially with idiopathic absence epilepsy (IAE)
(Sander et al., 2000). Significantly higher frequency of the 9-copy
allele of this polymorphism was observed in IGE and IAE
PWE compared to the control group (Sander et al., 2000).
In addition, various studies demonstrated that the A9 allele
(9-copy repeat) of the DAT gene contributed to the risk of
alcohol-withdrawal seizures and delirium (Sander et al., 1997;
Gorwood et al., 2003), suggesting that variations of the DAT
gene may modulate neuronal excitability and contribute to
epileptogenesis.
Genetics of Enzymes Involved in the Monoamine
Synthesis and Metabolism
Some insights about the involvement of the human
monoaminergic genes in epilepsy have come from a neurological
syndrome, which includes learning disabilities, epilepsy, and
psychiatric symptoms (Table 2). This syndrome is probably
caused by the mutation-induced deficiency of the 6 pyruvoyl
tetrahydropterin synthase, necessary for normal function of
tyrosine and tryptophan hydroxylases, enzymes enrolled in
the synthesis of monoamines (Ng et al., 2015). Moreover,
PWE with mental retardation carry an inherited duplication
(Tzschach et al., 2008; Klitten et al., 2011), or deletion (Whibley
et al., 2010) of Xp11.3, including genes coding for monoamine
oxidase A and B (MAO-A and MAO-B), suggested that these
genes are important for normal development of the CNS. This
is not surprising, as MAO-A and MAO-B play a role in the
degradation of monoamine neurotransmitters such as DA,
NA, and 5-HT. In PWE with idiopathic generalized epilepsies,
like childhood absence epilepsy, JAE, and juvenile myoclonic
epilepsy (Blümcke et al.), the functional polymorphism
located in the promoter of MAOA gene (MAOA-uVNTR)
was evaluated to test whether allelic variation has a role in
the etiology of IGE (Haug et al., 2000). Although, it was
expected that the higher activity promoter alleles (3a and 4
copy alleles) would be associated with susceptibility to epilepsy,
the frequencies of the high and low (3 copy allele) activity
allele groups were similar between PWE and controls, and
these results did not confirm any association between the
MAOA-uVNTR polymorphism and different IGE subtypes
(Haug et al., 2000). In line with these results, genetic variants of
MAOA-uVNTR polymorphism were also similarly distributed
among PWE with TLE and control subjects (Stefulj et al.,
2010).
Despite the large body of evidence reviewed here, relatively
scanty evidence from both animal and human studies is
available to support the direct association between epilepsy and
variation of genes involved in different aspects of monoaminergic
neurotransmission, including synthesis, metabolism, transport,
reuptake, or packaging (Ng et al., 2015).
MONOAMINERGIC STRATEGIES TO
TREAT EPILEPSY
As of yet, there are still no fully effective drugs for treating
epilepsy. Despite the emergence of new agents, a consistent
proportion of PWE remain resistant to drug treatments. It
appears clear that Paul Ehrlich’s “magic bullets” do not work
in complex CNS pathologies such as epilepsy for which “magic
shotguns” are instead needed (Roth et al., 2004). Indeed, single-
target AED may not always induce the desired effect even if
they successfully inhibit or activate a specific target known to be
altered in epilepsy (Csermely et al., 2005). One of the expansions
is that effectiveness can be affected in compensatory ways. There
is a need to develop multi-target anticonvulsants with the ability
to prevent or delay the onset of epilepsy and/or the potential for
disease modification.
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Unfortunately, in contrast to other CNS disorders (i.e.,
Alzheimer Disorder, AD), a multi-target ligand approach, acting
simultaneously on different receptors or enzymatic systems
implicated in epilepsy has not yet attracted the attention of
medicinal chemists. Specifically, targeting multiple monoamine
systems via multi-target-directed ligands (MTDL) may represent
a successful approach, since the experimental and clinical
evidence reviewed here has demonstrated the pivotal role of
different monoaminergic proteins/enzymes in epilepsy. The
rational discovery of multi-target drugs this may represent is an
emerging area in epilepsy. These drugs may be also useful for the
frequent comorbid psychiatric disorders seen in PWE (Bialer and
White, 2010; Cardamone et al., 2013).
Some of standard or herbal monoaminergic medicines already
show a profile of multi-target drugs acting via modulation of
multiple proteins/systems rather than single targets (Di Matteo
et al., 2000; Quesseveur et al., 2013), a phenomenon known as
polypharmacology (Hopkins, 2008).
Lu et al. (2012) compared the drug targets and the market
sales of the new molecular entities approved by the Food and
Drug Administration (FDA) using network analysis tools. There
are several monoaminergic targets, such as DARs, 5-HTRs,
ARs, MAO-B, etc., that are common to the CNS complex
diseases, confirming that these targets play crucial roles in the
development of complex diseases and in drug discovery (Lu et al.,
2012).
MAO Enzymes As Targets to Treat Epilepsy
MAO (EC 1.4.3.4, amine-oxygen oxidoreductase) exists as two
isozymes: MAO-A andMAO-B, both showing different substrate
specificities, sensitivity to inhibitors, and amino acid sequences.
MAO catalyzes the oxidative deamination of a variety of biogenic
and xenobiotic amines, with the concomitant production of
hydrogen peroxide (Youdim et al., 1988). MAO-A preferentially
oxidizes NA and 5-HT and is selectively inhibited by clorgyline,
while MAO-B preferentially deaminates β-phenylethylamine and
is irreversibly inhibited by l-deprenyl (Ramsay, 2013). MAO
activity has been shown to be linked to epilepsy since the 1960s
(Plotnikoff et al., 1963; Kohli et al., 1967). For instance, MAO-B
activity is elevated in hypometabolic regions of PWE with TLE
due to activated astrocytes and gliosis (Kumlien et al., 1992),
the most common histopathological abnormality seen in this
focal epilepsy (Blümcke et al., 2013). PET studies with 11C-
deprenyl (Kumlien et al., 2001) or autoradiographic studies in
human brain slices with 3H-deprenyl (Kumlien et al., 1992) have
therefore been used for identification of epileptogenic regions in
patients with focal epilepsy for surgical resection.
Although, several studies showed that the old MAO inhibitors
exhibit anticonvulsant activity (Plotnikoff et al., 1963; Kohen
et al., 1996), they have not been used clinically due to their
adverse effects. In addition, the magnitude of the anticonvulsant
response in animals models vary between MAO inhibitors
(MAO-I), while the role of MAO subtypes underscoring the
anticonvulsant action of MAO-I is not well understood. More
specifically, both selective MAO-A and MAO-B inhibitors
(MAO-AIs and MAO-BIs) exert anticonvulsant activity in
different preclinical models of seizure (Sparks and Buckholtz,
1985; Mukhopadhyay et al., 1987; Löscher and Lehmann, 1996,
1998; Loscher et al., 1999).
However, the anticonvulsant and the antiepileptogenic effects
of l-deprenyl, the most extensively studied drug in this respect,
seem to be mediated by MAO-A inhibition instead of the
irreversible MAO-B inhibition (Loscher et al., 1999). On
the one hand, this interpretation agrees with the lack of
anticonvulsant efficacy of the selective MAO-BI LU 53439, but
potent anticonvulsant activity of the selectiveMAO-AI esuprone,
in the kindling model of epilepsy (Loscher et al., 1999). These
results point strongly to MAO-A but not MAO-B inhibition as
an effective means of inducing anticonvulsant effects. On the
other hand, other MAO-BIs including safinamide or zonisamide
have been shown to be efficacious in some seizure models (Bialer,
2012; Park et al., 2015) and zonisamide was approved for epilepsy
recently (Bialer, 2012). Zonisamide has been shown to physically
interact with human MAO-B, but not MAO-A enzyme (Binda
et al., 2011) highlighting that MAO-B inhibition can be worth
targeting to achieve an anticonvulsant effect. The fact that MAO-
A could indirectly mediate the anticonvulsant properties of
MAO-BIs could be related to the complex relationships between
MAO-A and MAO-B. Indeed, despite the existence of preferring
substrates for each enzyme, the selective blockade of one enzyme
has been shown to alter the activity of the other one, particularly
after chronic administration (Youdim et al., 2006; Finberg, 2014).
In spite of the complex relationships between MAO-A and
MAO-B, these studies stress that MAO inhibition may be an
interesting strategy for developing novel anticonvulsant agents in
considering also the better tolerability of the newer compounds
compared to the early MAO-Is (Löscher and Lehmann, 1996,
1998; Loscher et al., 1999; Youdim et al., 2006; Bialer, 2012).
Aside from monoaminergic mechanisms, l-deprenyl has been
shown to affect the polyamine binding site of the NMDA subtype
of GLURs, to stimulate neurotrophic factors, and to modulate
gene expression and protein synthesis, which again is unrelated
to MAO-B inhibition (Magyar, 2011). Moreover, MAO-BIs seem
to be effective by acting on different pathways, along with
their enhancing effect on monoaminergic transmission. For
instance they possess neuroprotective properties (Aluf et al.,
2013) by blocking oxidative stress and ROS formation (Riederer
et al., 2004). Accordingly, compelling evidence supports the
idea that rasagiline-induced neuroprotection is not related to
the inhibition of MAO enzymatic activity. This action has been
ascribed to the presence of the reactive propargylamino moiety
which might interfere with many other cellular processes such
as different key steps of the apoptotic cascade (Al-Nuaimi et al.,
2012). In view of these various effects, it is impossible to foresee
which effect(s) are most likely to explain the anticonvulsant and
antiepileptogenic activity of l-deprenyl. Indeed, MAO-BIs show
multimodal effects and a MTDL profile (Pisani et al., 2011; Bolea
et al., 2013).
To date, the only MTDL strategy targeting monoaminergic
systems has focused on MAO inhibition among other targets
with cholinesterase (ChE) as a new strategy for AD (Bolea
et al., 2013) even if it has not yet led to novel clinical
therapeutics (Pisani et al., 2011) with the exception of
rasagiline (Youdim, 2003). Interestingly, some drug candidates
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have emerged from MTDL design showing promising multi-
target properties and have been submitted to extensive bio-
pharmacological profiling (Cavalli et al., 2008). Members
of the Cost ACTION CM1103 (http://www.cost.eu/COST_
Actions/cmst/CM1103) have designed, synthetized and evaluated
new different MTDL compounds acting on ChE and MAO-
I that may elicit better outcomes in the complex nature
of AD than the current selective drugs (Benek et al.,
2015; Ismaili et al., 2016; Unzeta et al., 2016). Moreover,
MAO-Is with additional ion-chelating and/or antioxidant
activities, compounds with dual MAO-I and adenosine A2aR
antagonist activity have been characterized (Pisani et al., 2011;
Guzior et al., 2015). Among these MTDLs based on MAO
inhibition, several compounds seem to be promising drug
candidates, while others may serve as a valuable inspiration
in the search for new effective therapies for epilepsy. Crucial
experimental evidence supporting these assumptions is now
warranted.
Monoamine Transporters As Targets to
Treat Epilepsy
The other important class of monoaminergic drugs that may
be useful for treating epilepsy is the monoamine transporters
(MATs). MATs (DAT, SERT, and NA transporter or NAT)
are transmembrane proteins located in plasma membranes
of monoaminergic neurons, while SERT is also expressed in
platelets (Amara and Kuhar, 1993). Due to amino acid sequence
and proposed structural similarity among the three plasma
membrane transporters, many MAT inhibitors have affinity for
all three transporters.
Antidepressants are commonly prescribed to PWE to
treat comorbid depression and/or anxiety. These include
selective serotonin reuptake inhibitors (SSRIs), serotonin-
noradrenaline reuptake inhibitors (SNRIs), and related
medications (Cardamone et al., 2013). Strikingly, several
preclinical and human studies have shown that antidepressants
have an anticonvulsant effect and in PWE can improve seizure
outcomes, with some patients experiencing dramatic and
complete seizure freedom during antidepressant treatment
(see Cardamone et al., 2013 for recent review of the
literature). Mounting experimental and clinical evidence
indicates that antidepressants are anticonvulsants, not
proconvulsants as was earlier believed (Jobe and Browning,
2005). Indeed, the proconvulsant effects of antidepressants
are mainly reported in cases of overdose, or when therapeutic
relevant doses are excessive for slow metabolizers (Preskorn
and Fast, 1992). Nevertheless, this erroneous convulsant
liability of antidepressants has hindered their use in
epilepsy.
SSRIs and SNRIs selectively inhibit monoamine reuptake at
the neuronal presynaptic membrane by blocking the 5-HT and
5-HT/NA reuptake transporters, respectively, increasing 5-HT
and/or NA levels in the synapse and in the peri-extrasynaptic
space. Serotonin and NA may therefore modulate neuronal
(i.e., excitability and release of other neurotransmitters) and
neuroglial activity. Different lines of enquiries have indicated
that SSRIs and SNRIs possess a wealth of potentially therapeutic
targets apart from simply increasing monoamine in the
CNS, including anti-inflammatory, antioxidant, neuroprotective,
and immunomodulatory effects, increase in the brain-derived
neurotrophic factor (BDNF), and modulation in the mTOR
pathway (Dale et al., 2015).
This list is by no means exhaustive, and other processes,
including genetic/genomic and epigenetic mechanisms may be
equally important. SSRIs and SNRIs may impact on the different
neurobiological alterations occurring in epileptogenesis, andmay
potentially influence disease course. Alper et al. (2007) reviewed
the effects of some SSRIs and SNRIs on seizure incidence in
a large cohort of non-epileptic patients in phase II and III of
FDA clinical trials of depression treatment between 1985 and
2004. Among the outputs of this study, it appeared that the
incidence of seizures occurring in depressed patients treated
with antidepressants was significantly lower, compared to those
treated with a placebo (Alper et al., 2007). Unfortunately,
there have been no double-blind, randomized controlled studies
yet; most of the studies have been small and on highly
selected patient populations recruited from epilepsy clinics or
following epilepsy surgery, and with few longitudinal, follow-up
studies.
It is possible that SSRIs and SNRIs, by targeting mechanisms
that are both involved in seizure generation and psychiatric
comorbidities, may induce both seizure suppression and
antidepressant effects. This multi-target profile possessed by
SSRIs and SNRIs provides them with the potential to meet
some of the criteria for MTDLs. The introduction of drugs
such as duloxetine for the treatment of major depression
(Carter and McCormack, 2009) indicates the clinical feasibility
of designing multifunctional ligands to treat CNS disorders with
complex disease pathways, such as epilepsy. Another example
is a class of compounds known as triple reuptake inhibitors
(i.e., amitifadine) that simultaneously block the synaptic reuptake
of 5-HT, NA, and DA (SNDRIs; Skolnick et al., 2006; Weng
et al., 2015). Again, as for the MAO-based MTDLs experimental
evaluation in animal models of epilepsy and in PWE is
needed.
Monoamine Receptors As Targets to Treat
Epilepsy
A more successful approach with fewer side effects would be
to selectively target some monoaminergic receptors instead
of increasing monoamine concentrations with MAO and/or
MAT inhibitors treatment. Based on the evidence reviewed
here, it might be inferred that the development of MTDLs
with optimal polypharmacological profile would exhibit, for
example, agonistic activity at 5-HT2CRs/D2Rs/α2-ARs and
antagonistic activity at H3Rs but also antagonistic effects
at 5-HT2CRs/MT1/2Rs (agomelatine). Polypharmacological
approaches are therefore likely to be extensively applied for
rational design of ligands with optimal multitarget profile and
for the discovery of multipotent drug candidates with improved
efficacy and safety in therapy of complex brain diseases (Nikolic
et al., 2016).
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NEW RESEARCH TRENDS IN
MONOAMINERGIC STRATEGIES TO
TREAT EPILEPSY
Epilepsy is no longer believed to be strictly a disturbance in
the functioning of neurons and specifically of their contact
points, the synapses. Instead, it is now seen as an imbalance
of the physiological extracellular milieu, due to a plethora of
different mechanisms. Therefore, the final imbalance between
excitation and inhibition in synaptic transmission that underlies
hyperexcitability of the epileptic brain (see van Gelder and
Sherwin, 2003 for a review) is far from being a mere direct
alteration of the excitatory glutamatergic and the inhibitory
GABAergic neurotransmission. Indeed, the pathophysiology
underlying ictogenesis and the development of epilepsy is very
complex, and clearly does not involve only neuronal cells. Much
recent evidence points to a significant contribution made by
glial cells to the pathophysiology of epilepsy (Devinsky et al.,
2013). This follows the new concept that glial cells interact
closely with neurons and play an active role in brain functions.
Astrocytes, the major type of glia, make direct contact with
neurons via a structure that has been defined as the tripartite
synapse, in which the astrocytic process is associated with the pre-
and post-synapse areas of neurons (Araque et al., 1999). Many
normal astrocytic functions are depressed in epilepsy, including
K+ homeostasis and accompanying changes in aquaporin, gap-
junction expression and function, local blood flow and the
blood-brain barrier (BBB), uptake and metabolism of GLU and
glucose in astrocytes, and neurotransmitter supply, particularly
in inhibitory neurons (see Devinsky et al., 2013; Coulter and
Steinhauser, 2015 for extensive reviews). Moreover, glial GABA
transporter-1 (GAT-1) activity in thalamic astrocytes is impaired
in absence epilepsy causing the enhanced GABA levels typical of
this generalized non convulsive epilepsy (Richards et al., 1995)
and leading to an aberrant GABAA receptor-mediated tonic
inhibition (Cope et al., 2009; Pirttimaki et al., 2013).
Emerging evidence suggests that also microglia cells, the CNS
resident macrophage cells, play important physiological roles at
synapses to such as extent that the concept of a quad-partite
synapse has been recently suggested (Schafer et al., 2013).
It is instead well-known that inflammation is due to microglia
activation and linked to different CNS diseases. For instance,
a large body of evidence indicates that inflammatory changes
sustained by uncontrolled glial-mediated immunity contribute
to epileptogenesis (Devinsky et al., 2013). Moreover, activated
microglia promote astrocytic activation and vice versa (Liu et al.,
2011), thus sustaining a vicious circle. All these biochemical
changes, often linked with gliosis, have significant functional
consequences, contributing to epileptogenesis.
Considering the fact that monoamines modulate human
behaviors and CNS functions, the antiepileptic, and
anticonvulsant action of monoamine ligands may be due to
their effect on different targets.
It is well-known that monoamines classically modulate cell
excitability by controlling release of GLU, GABA and, other
neurotransmitters and ion channels as we have reviewed (for
detailed reviews see also Ciranna, 2006; Fink and Goethert,
2007). However, it is a relative new evidence that astrocytes
contribute in the cellular action of antidepressants (Schipke
et al., 2011; Bernstein et al., 2015; Hertz et al., 2015).
Moreover, as further proof of a glial dysfunction in depression,
decreased density and number of glia cells has been observed in
cortical regions, including the prefrontal and cingulate areas in
humans (Rajkowska and Stockmeier, 2013), In addition, selective
destruction of frontocortical astrocytes (Banasr and Duman,
2008), NG2-expressing glia (NG2 glia) in the prefrontal cortex
(Birey et al., 2015) or pharmacological and genetic inhibition of
the activity of the glial glutamate transporter GLT-1 in subcortical
areas i.e., the lateral habenula (Cui et al., 2014), were capable of
triggering a depressive-like phenotype in rodents.
Astrocytes express virtually all of the receptor systems and
ion channels found in neurons (Verkhratsky and Kettenmann,
1996) including transporters critical for synaptic uptake of
glutamate (Tanaka et al., 1997) and GABA (De Biasi et al.,
1998). Monoamine receptors, (Azmitia et al., 1996), such as
5-HT2A/2B/2C receptors are expressed on astrocytes (Hirst et al.,
1998; Sanden et al., 2000; Hwang et al., 2008), but also 5-HT4,
5-HT5, and 5-HT7 receptors (Quesseveur et al., 2013), α-ARs
(Bekar et al., 2008) and β2-ARs (Mantyh et al., 1995), and all
the DA receptors (Miyazaki et al., 2004) are detected. The SERT,
NAT, DAT, and the catabolic isoenzymes responsible for the
degradation of monoamines (i.e., MAO-A and MAO-B; COMT)
were clearly identified in this cell type (see Quesseveur et al., 2013
for a recent review and references within). These observations
emphasize the fact that astrocytes can regulate the extracellular
monoamine levels by modulating the expression and function of
MAO-A, MAO-B, and COMT and at the same time are regulated
by feedback by monoamines via the glial monoamine receptors.
SSRIs citalopram and fluoxetine can excite astrocytes directly
by inducing astrocytic calcium transients that, differently from
the glutamate-induced calcium responses in astrocytes, occur
time-delayed, asynchronously and sometimes in an oscillatory
manner (Schipke et al., 2011).
Monoamines can change expression of various molecules
(Shishkina et al., 2012) involved in epileptogenesis acting
on microglial cells. The link between monoamines and
microglia is bidirectional. Indeed, microglial pro-inflammatory
cytokines, levels of which increase during epileptogenesis, can
decrease 5-HT, DA, and NA availability by acting on their
presynaptic reuptake transporters through activation of mitogen-
activated protein kinase pathways (Zhu et al., 2010) and by
reducing monoamine synthesis through decreasing enzymatic
co-factors such as tetrahydrobiopterin (Neurauter et al., 2008).
Moreover, many cytokines activate the enzyme indoleamine 2,3-
dioxygenase which converts tryptophan into kynurenine (Maes
et al., 2011).
From the analysis of the experimental and clinical evidence
reviewed here it is possible to hypothesize that a dysfunction
of the monoaminergic quad-partite synapse due to an insult
(i.e., neurotrauma, infectious injury, genetic disorders...) may
be a common pathophysiological mechanism of epilepsy and
mood disorders. Depending on the alterations of the quad-partite
synapse functions we might have particular mood disorders,
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epilepsy, or neuropsychiatric disorders with epilepsy (or vice
versa?). In the latter scenario, depression may be a biologic
marker for more severe epilepsy since it is a predictor of a worse
seizure outcome in PWEwith TLE (Kanner et al., 2003; Figure 1).
Some of the antiepileptic/antiepileptogenic effects exerted by
monoamines might be due to their ability to act on glia targets.
For instance, we have suggested that Ro 60-0175 may normalize
the aberrant enhanced GABAA tonic current of the thalamic
neurons of GAERS (Cavaccini et al., 2012) by activating astrocytic
5-HT2CRsthat increase activity of glial GAT-1 transporter leading
to a reduction of extrasynaptic GABA levels. This hypothesis
reinforce the idea of a glial dysfunction in epilepsy and glial
cells as new therapeutic targets for this disorder (Crunelli and
Carmignoto, 2013; Crunelli et al., 2015). Nevertheless, the role
of 5-HT in the function of glial GABA transporters and in
general in themodulation of GABA homeostasis, although earlier
suggested (Voutsinos et al., 1998), remains to be fully investigated
in epilepsy. Interestingly, other early findings showed that 5-HT
is capable of modulating the activity of glial Na+/K+-ATPase but
not in the kindled glial fraction (Hernandez and Condes-Lara,
1989). The failure of this 5-HT control of reactive astrocytes due
to repeated seizures may contribute to seizure-like activity and
epileptogenesis.
CONCLUSION
In this review, recent evidence from both animal and human
studies supporting the role of monoamines in epilepsy was
described. The possible therapeutic application of these findings
has been long disregarded, mainly due the severe side effects
of some monoaminergic drugs or due to interpretative bias on
research evidence.
As further reasons of this stall are that the both the
pathophysiological mechanisms underlying epileptogenesis
and the genetics of epilepsy are still not clear. Therefore,
further research on different aspects of monoaminergic
neurotransmission using human genetic biomarkers in
combination with novel animal genetic models, might elucidate
the complex role of monoamines in the pathophysiology of
FIGURE 1 | Hypothetical monoaminergic quad-partite synapse dysfunction as a common pathological mechanism of mood disorders and epilepsy.
The processing of information in synapses is not only defined by neurons, but also by glia cells, namely by astrocytes, which enwrap synapses, and microglia, which
dynamically interact with synapses in an activity-dependent manner. This new evidence has brought the development of the quad-partite synapse model, as a further
evolution of the tripartite synapse, made up of four elements i.e., presynaptic and postsynaptic neuronal terminals, astrocyte and microglia cells (Schafer et al., 2013).
Numerous lines of evidence support the contention that a modification of the quad-partite synapse astrocytes and microglia in different brain regions is associated
with depression, and epilepsy (Crunelli and Carmignoto, 2013; Quesseveur et al., 2013). We propose that there may be shared underlying pathology that predisposes
patients to depression, epilepsy or both seizures and depression (the latter “seizure/depression phenotype”). For example, traumas, infective disease, early life stress,
hormonal changes, genetic and developmental defects, just to cite a few, might induce a dysfunction of the monoaminergic quad-partite synapse and different
pathogenic scenarios might cause depression, epilepsy or both conditions. The underlying pathology in the monoaminergic systems of patients with epilepsy (PWE)
lowers the threshold for seizures, while also increasing the risk of depression. Moreover, PWE suffering of mood disorders have a higher risk to develop severe and
drug-resistant epilepsy (Kanner et al., 2003) and sudden unexpected death in epilepsy (SUDEP; Richerson and Buchanan, 2011). Arrows indicate hypo- or
hyperfunction of the glial cells.
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epilepsy and might accelerate development of novel therapeutic
strategies targeting various components of monoaminergic
systems. This is desperately needed, firstly because the number
of anti-seizure drugs in clinical development has been decreasing
over the years (Bialer et al., 2013) and secondly for the increasing
number of PWE with refractory epilepsy. Therefore, the
beneficial effects of ligands at D2R, 5-HT2CR, MTRs, α-ARs,
H3Rs, MAO-Is, and MTAs inhibitors observed in both animal
and human epilepsy would deserve more attention both from
preclinical and clinical researchers and above all medicinal
chemists.
In our opinion, adequate control of epileptogenesis and
convulsions and comorbid psychiatric disorders will likely benefit
from MTDLs that target different synergistic monoaminergic
pathways and different elements of the quad-partite synapse.
Nevertheless, their synthesis and experimental validation needs
significant efforts and time. There is a scientific and economic
incentive for their synthesis as anti-epileptic and/or anti-
epileptogenic drug targets. Newmonoaminergic drugs with fewer
side effects and a multi-target profile are warranted.
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